================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D. C. 20549
FORM 10-KSB/A
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 1997
Commission File Number 0-10683
HYDROMER, INC.
-----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 22-2303576
------------------------------ ------------------------------
(State of incorporation) (I.R.S. Employer
Identification No.)
35 Columbia Road, Branchburg, New Jersey 08876-3518
- ------------------------------------------ ------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (908) 526-2828
---------------
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock Without Par Value
------------------------------
(Title of class)
Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such report(s), and (2) has been subject to such filing requirements for the
past 90 days. Yes (X) No ( )
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10KSB
or any amendment to this Form 10KSB (X)
The aggregate market value of the voting stock held by non-affiliates of
the Registrant at September 3, 1996 was approximately $308,673
The number of shares of Registrant's Common Stock outstanding on December
31, 1997 was 4,367,987 as reported in the Company's Form 10-QSB for the three
months ended December 31, 1997.
Portions of the Annual Report to Stockholders for the fiscal year ended
June 30, 1997 are incorporated by reference in Part II of this report. Portions
of the Proxy Statement of Registrant dated September 3, 1997 are incorporated by
reference in Part III of this report.
================================================================================
<PAGE>
PART IV
Item 13. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) 1. Financial Statements:
The financial statement of the Company incorporated as Exhibit 13 in
the Annual Report in this Report.
(a) 3. Exhibits:
The exhibits required to be filed as part of this Report are listed in
the attached Index to Exhibits.
(b) Current Reports on Form 8-K:
The Company has not filed any Current Reports on Form 8-K during the
quarter ended June 30, 1997.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
HYDROMER, INC.
/s/ MANFRED F. DYCK President, Principal Executive Officer, February 23, 1998
- --------------------- Chairman of the Board of Directors
Manfred F. Dyck
/s/ MARK KLYPKA Vice President Finance & February 23, 1998
- --------------------- Administration Chief Financial Officer
Mark Klypka
Pursuant to the requirements of the Securities and Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated:
/s/ MANFRED F. DYCK President, Principal Executive Officer, February 23, 1998
- --------------------- Chairman of the Board of Directors
Manfred F. Dyck
/s/ URSULA M. DYCK Director February 23, 1998
- --------------------
Ursula M. Dyck
Director September __, 1997
- --------------------
Dieter Heinemann
/s/ MAXWELL BOROW Director February 23, 1998
- --------------------
Maxwell Borow
/s/ ROBERT H. BEA Director February 23, 1998
- --------------------
Robert H. Bea
3
<PAGE>
INDEX TO EXHIBITS
13 Annual Report to Shareholders for the fiscal year ended June 30,
1997.
4
[Logo] HYDROMER [REPEAT DESIGN]
[GRAPHIC]
to the Next Level
Taking Hydrophilic Coating
1997 Annual Report
<PAGE>
[REPEAT DESIGN]
COMPANY PROFILE
Hydromer is an innovative, technology-focused company engaged in the business
of inventing, developing, patenting, licensing, manufacturing, and selling
hydrophilic polymer-based products for commercial markets. While maintaining
its industry leadership position in permanent lubricious coatings for medical
devices, Hydromer constantly strives to build upon its current
technologies--successfully expanding its technology/product base to include
anti-fog and condensation control coatings for optical plastics,
water-resistant filmformers for cosmetics, unique hydrogels for medical and
cosmetic applications and barrier lotions for the prevention of contact
dermatitis.
<PAGE>
SELECTED FINANCIAL DATA
Fiscal Year Fiscal Year
Ended Ended
JUNE 30, 1997 June 30, 1996
-----------------------------
As Restated
Revenues...................................... $2,062,026 $1,698,358
-----------------------------
Operating Income.............................. 393,804 123,485
-----------------------------
Interest Income............................... 14,047 10,483
-----------------------------
Net Income.................................... 344,394 389,619
-----------------------------
Income per Common Share....................... .08 .09
-----------------------------
Weighted Average Number of Shares of
Common Stock Outstanding
(Including Dilutive Options)................. 4,367,987 4,367,987
-----------------------------
Cash Dividends................................ -- --
-----------------------------
Total Assets.................................. $2,020,082 $1,534,707
=============================
STOCK INFORMATION
Prior to January 9, 1986, the Company's Common Stock was traded in the
Over-the-Counter Market on the National Association of Securities Dealers'
Automated Quotation System (NASDAQ) under the symbol HYDI. Subsequent to January
9, 1986, reporting of trading was transferred to the National Daily Quotation
Service (commonly known as "Pink Sheets"). For the past seven years, trading in
the Company's stock has been limited. The Company has been informed by
individual investors of trades at prices ranging between $.50 and $.0625 in
the fiscal year 1997 and between $.1875 and $.0625 in fiscal year 1996. Prices
for the 1995 fiscal year have ranged between $.25 and $.03125 according to the
National Quotation Bureau, Inc. These prices may not include retail mark-ups or
mark-downs or any commission to the broker dealer.
The approximate number of holders of record of the Common Stock on August
31, 1997 was 323.
- -------------------------------[Logo]HYDROMER----------------------------------1
<PAGE>
LETTER TO SHAREHOLDERS
In fiscal 1997 Hydromer posted net income of $344,394 or $.08 per share, on
revenues of $2,062,026, as compared with a restated net income of $389,619 or
$.09 per share, on revenues of $1,698,358 recorded in fiscal year 1996.
Hydromer has seen its total assets grow to over two million dollars. Our
rather diverse business, mostly based on our own patents, covers cosmetic
ingredients, medical coatings and condensation control formulations. These
three products accounted for 71% of total product sales.
Total product sales increased from $632,307 to $748,006, an 18% increase,
while royalty income increased from $1,066,051 to $1,314,020, a 23% increase.
During the first quarter of fiscal 1998 one of our patents will expire and
another in the third quarter with a concomitant loss of royalty income. However,
management believes that new patents and an increased stream of royalty income
will mitigate any lasting negative effect.
We continue to focus on the basic philosophy of the Company to develop new
patentable technologies. The Company presently has 10 U.S. and 6 international
patents, most going well into the year 2000. Additionally, two new technologies
centering around allergen blockers and biostatic complexes are presently patent
pending.
We remain committed to sell our technologies either as licenses and/or as
basic raw materials, with customers in very diverse industries:
. Medical Devices
. Cosmetics
. Personal Care Products
. Condensation Control
. Anti-Fog
In fiscal 1997 we signed up several new distributors for Europe and Asia
and were able to train key people at two domestic and international exhibitions.
Fiscal 1998 will see us expanding our scientific staff and adding
sophisticated scientific instrumentation, which should further expand our base
technology development. This will also allow us to better serve our customers.
We are striving to enhance our international contacts and our goal is to obtain
a significant portion of our revenue from international sales. This fiscal year
should be exciting and have us achieve some remarkable goals.
Respectfully submitted,
/s/ M.F. Dyck
M.F. Dyck
Chairman and President
2-------------------------------[Logo]HYDROMER----------------------------------
<PAGE>
BUSINESS
GENERAL
Hydromer, Inc. (the "Company") is a polymer research and development
company organized as a New Jersey Corporation in 1980 for the purpose of
developing polymeric complexes for commercial markets in the medical and
industrial fields. The Company owns several process and applications patents for
Hydromer(R) ("Hydromer"), which is both a polymeric substance that becomes
extremely lubricious (slippery) when contacted by water and a technique of
grafting or applying this substance onto surfaces which may consist of a wide
variety of materials, including polyurethane, polyvinyl chloride, and metals.
"Hydromer(R)" is a trademark of the Company. The Company has also been issued
patents for a permanent anti-fog material, a hydrophilic polyurethane foam,
hydrophilic polyurethane blends, hydrophilic polyvinylbutyral alloys, several
different biocompatible hydrogels and an anti-bacterial medical material, and
owns a trademark Sea-Slide(R), a coating for boats, which the Company is
marketing. Other patent applications have been filed.
From its inception in 1980 to mid-1984, the Company was engaged primarily
in research and development activities relating to Hydromer coatings. The
Company believes that the polymer and water interface of Hydromer provides a
surface lubricity superior to the quality of other presently marketed
silicone-based lubricants used to treat medical devices. When treated with
Hydromer coating, a medical device becomes highly slippery upon contact with
water, facilitating its insertion into any orifice of the body, in particular,
the nasal/oral, rectal and urinary orifices, or penetration through the skin,
thus reducing discomfort for the patient. Hydromer coatings are bonded to the
medical device unlike silicone-based lubricants, which must be re-applied after
each use of the medical device. During its fiscal year ended June 30, 1997, the
Company entered into three license agreements for the use of Hydromer. Hydromer
has license agreements with eighteen different companies covering the
application of Hydromer coatings to the following devices: heart pacemaker
leads, wound drains, enteral feeding products, guide wires, intermittent urinary
catheters, certain urological devices, central venous catheters, ear prostheses,
guiding catheters, razor cartridges and angioplasty balloon catheters,
embolization delivery devices, biliary and pancreatic stents, umbilical
catheters, infusion catheters for peripheral and neurological uses and certain
urological devices.
The Company believes that Hydromer technology may have further application
both in connection with medical products and products outside the medical field.
During the 1986 fiscal year, the Company was granted a U.S. Patent for
hydrophilic polyurethane foam and dental and biomedical products fabricated
therefrom. This foam has been independently tested and exhibits superior
absorptivity, high tensile strength when wet and reduced peel adhesion to the
skin.
In addition to its foregoing activities, the Company is marketing the
following products based on its polymer technology:
Anti-Fog--a coating for plastics (e.g., ski and swim goggles) which
prevents the accumulation of vision-obscuring condensation under high humidity
conditions. A more advanced version of anti-fog coating was patented in August
1984 and is being sold in bulk to manufacturers of industrial safety and swim
goggles, aircraft windows and meter covers. Condensation control coatings have
been developed for use on greenhouses and food packaging.
Sea-Slide(R)--a Hydromer-based drag reducing marine coating which reduces
friction between hull and water, and can be used over most anti-fouling paints.
A U.S. Patent covering this coating and other potential uses was issued in
February 1987.
Cosmetic formulations--aqueous-based polymer blends were introduced during
1988 and are protected by the polymer blends patent issued in February 1987.
These formulations are being sold to major cosmetic firms for use in hair dyes,
hair conditioners, mascaras, eye shadows and body lotions and are being tested
for use in shampoos and sunscreens.
Hydromer(R) Poison Oak and Ivy Barrier--a barrier lotion that protects the
wearer from the effects of poison ivy, poison oak, and poison sumac plant
allergens.
Until September 1982, approximately 99% of the outstanding common stock,
without par value (the "Common Stock"), of the Company was owned by Biosearch
Medical Products Inc. ("BMP"), which in turn was controlled by Manfred F. Dyck,
who is Chief Executive Officer, a Director and the Chairman of the Board of the
Company. On September 16, 1982, BMP distributed its shareholdings in the
Company pro rata to the holders of its common stock. In connection with this
distribution, the Company granted to BMP an exclusive, world-wide perpetual,
royalty-free license to use the Hydromer technology in connection with the
development, manufacture and marketing of biomedical devices for enteral feeding
applications.
PRODUCTS
Coating solutions for use on medical devices are manufactured and sold by
the Company to its licensees and others. The Company has received a United
States and foreign patents for a permanent type anti-fog coating. The Company is
selling bulk quantities of anti-fog solution to manufacturers of swim goggles,
industrial safety equipment, aircraft windows and meter covers, both in the U.S.
and foreign countries.
The Company has developed a condensation control coating for use on
structured greenhouse coverings, which it sells to a major corporation that
manufactures this material in the U.S. and Europe.
A food packaging coating has been formulated using only materials that are
generally recognized as safe for food contact, and independent laboratory
extraction tests of the coating have demonstrated that the extractibles are well
within levels specified by the FDA.
Another product introduced in 1984 was "Sea-Slide(R)", a drag reducing
overcoating for boats and ships. This product is designed to improve fuel
efficiency by lowering the friction between hull and water. It is being marketed
through a repackager and distributor who services the marine industry.
Sea-Slide(R) has been shown at major marine shows. Bulk quantities are also
being sold to distributors in Europe who package the product for local markets.
- -------------------------------[Logo]HYDROMER----------------------------------3
<PAGE>
In the 1988 fiscal year, the Company introduced aqueous-based formulations
for use as a component in beauty aids. This product is being marketed through
distributors in the U.S. and abroad and is currently being sold for use in
mascaras, hair dyes, hair conditioners, hair shampoos, eye shadows, hair
colorings, hair sprays, body lotions and perfumes.
In the 1996 fiscal year the Company introduced our very first
consumer-oriented product, Hydromer(R) Poison Oak and Ivy Barrier. We have
developed national accounts for this product representing a cross section of
pharmacies, sporting goods and specialty stores (country clubs, campsites,
resorts). We also are seeing a great deal of interest from the tree care,
landscaping and utility lines clearance industries. Chain drug stores and mass
marketers have also indicated an interest in Hydromer(R) Poison Oak and Ivy
Barrier.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The discussion below analyzes major factors and trends regarding the
results of operations and the financial condition of the Company as of June 30,
1997, and its results of operations for prior fiscal periods. It should be read
in conjunction with the Financial Statements and Notes thereto.
RESULTS OF OPERATIONS
Revenues of $2,062,026 in the 1997 fiscal year were $363,678 greater than
the restated $1,698,358 of revenues recorded in the 1996 fiscal year. Royalty
income of $ 1,314,020 was $247,969 or 23% greater than the restated $1,066,051
recorded in the 1996 fiscal year. Sales of coating solutions and chemicals sold
to licensees were $271,981 as compared to $188,024 in the previous fiscal year.
Sales of anti-fog coating solutions and other condensation control solutions
were $253,553, as opposed to $210,932 in the previous fiscal year. The 20%
increase is due to the volume increase in the anti-fog coating solutions. Sales
of cosmetic ingredients were $198,401, as opposed to $226,439 in the previous
fiscal year. Other miscellaneous revenues were $24,071 as compared to $6,912 in
the 1996 fiscal year.
Cost of sales of $242,025, or 32% of the sales of products and services in
the 1997 fiscal year were $11,399 greater than the $230,626, or 36% of the sales
of products and services in the 1996 fiscal year. The percentage of cost of
sales increased 5% due to the change in the product mix as compared to the
previous fiscal year.
In fiscal year 1997 the Company had net income of $344,394 as compared to a
restated net income of $389,619 for fiscal year 1996, reflecting a decrease of
$45,225. The decrease in net income was the direct result of the Company being
taxed as a personal holding company. Owing to the nature of the Company's income
(royalties accounting for over 60%) and the number of its controlling
shareholders, the Company was classified as a personal holding company (PHC)
for the current fiscal year, resulting in an estimated $95,000 federal tax
liability. Although the Company has taken steps to restructure its operations to
avoid PHC status, the unanticipated payment in fiscal 1997 of substantial
royalties by a licensee for the current and prior fiscal years caused the
Company to fall into PHC status. The Company's gross profit of 88% in fiscal
1997 was relatively unchanged from the 85% in fiscal 1996. The reason for the
small increase gross profit can be attributed to the combination of the change
in product mix and the increase in royalty income.
Selling, general and administrative expenses in the 1997 fiscal year of
$1,041,601, or 51% of revenues were $195,926, or 23% greater than the $845,675,
or 50% of revenues reported in fiscal 1996. Research and development expenses of
$384,596 or 19% of revenues were $113,976, or 23% less than the $498,572, or 29%
of revenues in fiscal 1996. The increases in total expenses were a result of
increased costs associated with the hiring of a Director of Sales and Marketing
for Industrial and Medical Applications and an increase of legal expense on
patents.
Interest income was earned in the amount of $14,047 and $10,483 in the
fiscal years ended June 30, 1997 and 1996, respectively, on short-term
investments. The increase was attributed to the increase in the amount of
short-term investments. Included in other income for fiscal 1996 is $85,000 the
company received as a settlement with its former auditors regarding prior period
income tax liabilities owed as a result of being classified as a personal
holding company.
Reflecting the predominant research and development nature of the Company's
activity to date, the Company has a cumulative loss of $1,711,350 as of June 30,
1997.
Provision for income taxes was $(31,624) and $(167,463) in the 1997 and
1996 fiscal years, respectively.
LIQUIDITY AND CAPITAL RESOURCES
Working capital as of June 30, 1997 was $1,136,401.
Management believes that the Company will continue to generate sufficient
funds to maintain its current level of operation. As existing licensees continue
to increase the volume of products they are coating, additional licenses are
negotiated for use of the Hydromer(R) coating and the anti-fog coatings gain
greater recognition in the marketplace. Another product that could significantly
increase future revenues is Hydromer Poison Oak and Ivy Barrier.
The major components of the Company's current assets are cash, cash
equivalents and accounts receivable. Inflation has not been a major factor in
past operations of the Company. The Company believes that its products are
sufficiently unique to permit recovery of inflationary cost increases in its
pricing.
4-------------------------------[Logo]HYDROMER----------------------------------
<PAGE>
BALANCE SHEETS
June 30,
--------------------------
1997 1996
--------------------------
As Restated
ASSETS
Current Assets
Cash and cash equivalents....................... $ 716,045 $ 167,900
Trade receivables less allowance for doubtful
accounts of $8,831 in both 1997 and 1996....... 431,150 624,271
Inventory....................................... 148,753 171,360
Prepaid expenses................................ 77,567 45,262
Deferred tax asset.............................. 100,000 62,000
--------------------------
Total Current Assets.......................... 1,473,515 1,070,793
Property and Equipment, net....................... 271,743 222,514
Deferred Tax Asset................................ 262,856 231,525
Other............................................. 11,968 9,875
--------------------------
Total Assets.................................. 2,020,082 1,534,707
==========================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable................................ 29,213 22,356
Accrued expenses................................ 167,678 70,261
Income tax payable.............................. 40,223 3,516
--------------------------
Total Liabilities............................. 237,114 96,133
--------------------------
Stockholders' Equity
Common stock--no par value, authorized
6,000,000 shares, issued and outstanding,
4,378,904 shares.............................. 2,922,708 2,922,708
Contributed capital............................. 577,750 577,750
Accumulated deficit............................. (1,711,350) (2,055,744)
Treasury stock, 10,917 common shares at cost.... (6,140) (6,140)
--------------------------
Total Stockholders' Equity.................... 1,782,968 1,438,574
--------------------------
Total Liabilities and Stockholders' Equity.... $2,020,082 $1,534,707
==========================
See notes to the financial statements.
- -------------------------------[Logo]HYDROMER----------------------------------5
<PAGE>
STATEMENTS OF INCOME
Year Ended June 30,
-------------------------
1997 1996
-------------------------
As Restated
REVENUES
Sales of products and services.................. $ 748,006 $ 632,307
Royalties, options and licenses................. 1,314,020 1,066,051
-------------------------
2,062,026 1,698,358
Cost of Sales.................................... 242,025 230,626
-------------------------
Gross Profit..................................... 1,820,001 1,467,732
-------------------------
Operating Expenses
Selling, general and administrative............ 1,041,601 845,675
Research and development....................... 384,596 498,572
-------------------------
1,426,197 1,344,247
-------------------------
Operating Income................................. 393,804 123,485
Other Income (Expense)
Interest income................................ 14,047 10,483
Other income................................... -- 88,178
Other tax expense.............................. (95,081) --
-------------------------
Income Before Taxes.............................. 312,770 222,146
Income tax (benefit)............................. (31,624) (167,473)
-------------------------
Net Income....................................... $ 344,394 $ 389,619
=========================
Income Per Common Share.......................... $ .079 $ .089
=========================
Shares Used in Computation....................... 4,367,987 4,367,987
=========================
See notes to the financial statements.
6-------------------------------[Logo]HYDROMER----------------------------------
<PAGE>
STATEMENT OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
Unrealized
Gain (Loss) on
Common Stock Marketable Treasury Stock
------------------------- Contributed Investment Accumulated ---------------
Shares Amount Capital Securities Deficit Shares Amount Total
-----------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance June 30, 1995....... 4,378,904 $2,922,708 $577,750 $ 1,021 $(2,607,363) 10,917 $(6,140) $ 887,976
Prior period adjustment..... -- -- -- -- 162,000 -- -- 162,000
Change in unrealized gain
(loss) on marketable
investment securities..... -- -- -- (1,021) -- -- -- (1,021)
Net Income (as restated).... -- -- -- -- 389,619 -- -- 389,619
-----------------------------------------------------------------------------------------------------
Balance June 30, 1996
(as restated).............. 4,378,904 2,922,708 577,750 -- (2,055,744) 10,917 (6,140) 1,438,574
Net Income.................. -- -- -- -- 344,394 -- -- 344,394
-----------------------------------------------------------------------------------------------------
BALANCE JUNE 30, 1997....... 4,378,904 $2,922,708 $577,750 $ -- $(1,711,350) 10,917 $(6,140) $1,782,968
=====================================================================================================
</TABLE>
See notes to the financial statements.
- -------------------------------[Logo]HYDROMER----------------------------------7
<PAGE>
STATEMENTS OF CASH FLOWS
Year Ended June 30,
------------------------
1997 1996
------------------------
As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income........................................ $344,394 $ 389,619
Adjustments to Reconcile Net Income to Net
Cash Provided by (Used in) Operating Activities
Depreciation and amortization................... 43,326 34,769
Gain on sale of securities...................... -- (1,851)
Changes in Assets and Liabilities
Trade receivables............................... 193,121 (193,862)
Inventory....................................... 22,607 (89,989)
Prepaid expenses................................ (32,305) (36,716)
Deferred tax asset.............................. (69,331) (171,030)
Other assets.................................... (2,093) (75)
Accounts payable and accrued liabilities........ 104,274 32,882
Income taxes payable............................ 36,707 (35,047)
------------------------
Net Cash Provided by (Used in) Operating
Activities................................... 640,700 (71,300)
------------------------
CASH FLOWS FROM INVESTING ACTIVITIES
Cash purchases of property and equipment.......... (92,555) (74,024)
Cash proceeds received from sale of marketable
investment securities............................ -- 462,194
Cash purchases of marketable
investment securities............................ -- (190,000)
------------------------
Net Cash (Used in) Provided by Investing
Activities................................... (92,555) 198,170
------------------------
Net Increase in Cash and Cash Equivalents........... 548,145 126,870
Cash and Cash Equivalents at Beginning of Year...... 167,900 41,030
------------------------
Cash and Cash Equivalents at End of Year............ $716,045 $ 167,900
========================
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the year for:
Interest........................................ $ -- $ 253
Income taxes.................................... $ -- $ 38,658
See notes to the financial statements.
8------------------------------[Logo]HYDROMER----------------------------------
<PAGE>
NOTES TO THE FINANCIAL STATEMENTS
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
Hydromer, Inc. (the "Company") is a polymer research and development
company based in Branchburg, New Jersey. The Company develops polymer complexes
for commercial markets in the medical and industrial fields primarily in the
United States. The Company obtains patent rights on certain products from which
royalty revenues are received.
Cash and Cash Equivalents
Cash and cash equivalents consist of short term investments with maturities
of three months or less.
Inventories
Inventories are valued at the lower of cost, determined by the first-in,
first-out method, or market and include appropriate amounts of labor and
overhead.
Depreciation
The cost of property and equipment is depreciated on a straight-line method
over the estimated useful lives of the assets: 10 years for machinery and
equipment, 5 years for furniture and fixtures, and the term of the lease for
leasehold improvements. When assets are retired or otherwise disposed of, the
cost and related accumulated depreciation are removed from the accounts, and any
resulting gain or loss is reflected in income for the period. Repairs and
maintenance which do not extend the useful lives of the related assets are
expensed as incurred.
Income Taxes
Income taxes are provided for the tax effects of transactions reported in
the financial statements and consist of taxes currently due plus deferred taxes
related primarily to differences between the bases of assets and liabilities for
financial and income tax reporting. The deferred tax assets and liabilities
represent the future tax return consequences of those differences, which will
either be taxable or deductible when the assets and liabilities are recovered or
settled. Deferred taxes also are recognized for operating losses that are
available to offset future federal and state income taxes.
Income Per Common Share
Income per common share was computed by dividing net income by the weighted
average number of shares of common stock outstanding during each period.
Concentration of Credit and Business Risk
The Company maintains cash balances in a financial institution. Accounts at
the institution are insured by the Federal Deposit Insurance Corporation up to
$100,000. At June 30, 1997, the amounts on deposit exceeded the $100,000
federally insured limit. The Company provides credit in the normal course of
business to customers. Ongoing credit evaluations of its customers are
performed, and allowances for doubtful accounts are based on factors surrounding
the credit risk of specific customers, historical trends, and other information.
The Company maintains patents on the original Hydromer Coating which will expire
during fiscal year ended June 30, 1998.
Major Customers
The Company sold products and collected royalty income representing more
than 10% of its total revenues for the year ended June 30, 1997, to Cordis
Corporation and Warner Lambert; for the year ended June 30, 1996, to Cordis
Corporation and Phoenix Chemical Inc.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
INVENTORY
Inventory consists of:
June 30,
---------------------
1997 1996
---------------------
Raw materials.................................. $ 86,580 $ 87,558
Finished goods................................. 62,173 83,802
---------------------
$148,753 $171,360
=====================
MARKETABLE INVESTMENT SECURITIES
Information regarding available-for-sale marketable investment securities
is as follows:
June 30,
-----------------------
1997 1996
-----------------------
Carrying value.................................... $ -- $ --
Market value...................................... -- --
-----------------------
Gross unrealized gain............................. $ -- $ --
=======================
Change in unrealized gain
on investment securities......................... $ -- $ 1,021
Proceeds from sales............................... $ -- $ 272,194
Realized gains on sales........................... $ -- $ 1,851
- -------------------------------[Logo]HYDROMER----------------------------------9
<PAGE>
PROPERTY AND EQUIPMENT
Property and equipment consists of the following:
June 30,
-----------------------
1997 1996
-----------------------
Machinery and equipment............................. $ 476,765 $ 406,200
Furniture and fixtures.............................. 108,906 92,849
Leasehold improvements.............................. 189,605 183,672
-----------------------
775,276 682,721
Less accumulated depreciation and
amortization....................................... (503,533) (460,207)
-----------------------
$ 271,743 $ 222,514
=======================
Depreciation expense charged to operations was $43,326 and $34,769 in 1997
and 1996, respectively.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amount of cash and equivalents, accounts receivable, accounts
payable and accrued expenses approximates fair value because of the short
maturity of these instruments.
Limitations
Fair value estimates are made at a specific point in time, based on
relevant market information about the financial instrument. These estimates are
subjective in nature and involve uncertainties and matters of significant
judgment and therefore cannot be determined with precision. Changes in
assumptions could significantly affect the estimates.
INCOME TAXES
The income tax provision (benefit) is comprised of the following:
Federal State Total
---------------------------------
YEAR ENDED JUNE 30, 1997
CURRENT................................. $ -- $ 36,707 $ 36,707
DEFERRED................................ (68,331) -- (68,331)
---------------------------------
$ (68,331) $ 36,707 $ (31,624)
=================================
Year Ended June 30, 1996
Current................................. $ -- $ 100 $ 100
Deferred................................ (167,563) -- (167,563)
---------------------------------
$(167,563) $ 100 $(167,463)
=================================
The temporary differences causing such deferred tax benefits are primarily
due to net operating loss carryforwards.
At June 30, 1997, the Company has net operating loss carryforwards for
federal income tax purposes of $1,064,282, which are available to offset future
federal taxable income, if any. The federal net operating loss carryforwards
expire as follows:
Federal
-------------
2000............................................... $ 274,048
2001............................................... 198,315
2002............................................... 138,889
2003............................................... 58,675
2010............................................... 394,355
-------------
$ 1,064,282
=============
The tax effects of temporary differences that give rise to deferred tax
assets at June 30, 1997 are presented below:
Federal operating loss carryforwards............... $ 362,856
=============
OTHER INCOME
Included in other income for the year ended June 30, 1996 is $85,000 the
Company received as a settlement with its former auditors regarding prior period
income tax liabilities owed as a result of being classified as a personal
holding company.
OTHER TAX EXPENSE
Included in other taxes for the year ended June 30, 1997 is $95,081 the
Company owes as a penalty tax for being classified as a personal holding
company.
STOCK OPTIONS AND AWARDS
On January 23, 1992, the Board of Directors granted options to purchase
12,000 shares of common stock of the Company which were to expire on
January 22, 1997, with 4,000 shares being exercisable immediately, 4,000
becoming exercisable one year from the date of the grant, and the final 4,000
becoming exercisable two years from the date of the grant. The exercise price
of $0.625 per share was equal to the market price at the date of the grant. At
June 30, 1997, the 12,000 options exercisable under this arrangement have
expired.
In the 1988, 1989 fiscal years and a portion of 1990, the Board of
Directors determined that, in lieu of cash compensation, Directors were to
receive options to purchase 2,000 shares of stock for attendance at each meeting
of the Board at the then current market price of the stock. The options are to
expire five years from date of grant. Fifty-four thousand shares were granted
under this option. The option prices range from $0.50 to $0.81.
10------------------------------[Logo]HYDROMER----------------------------------
<PAGE>
On January 22, 1993, the Board offered all holders of options (3 current
directors and 2 former directors) the right to extend their options to 1995 upon
payment of an amount equal to 10% of the market value ($0.50/share). The current
Directors, Manfred Dyck and Ursula Dyck, and the former director, John H. Ewing,
elected to extend their 1988 options. Only Manfred Dyck and Ursula Dyck elected
to extend their 1989 options. Options were not re-priced. Thirty-six thousand
and 8,000 option shares under this arrangement expired in 1995 and 1994,
respectively. At ~June 30, 1995, 4,000 option shares under this arrangement were
exercisable. At June 30, 1996, the 4,000 option shares exercisable under the
January extension have expired.
A summary of activity under the plan for the years ending June 30, 1997 and
1996 is as follows:
Common Stock
Options Outstanding
-------------------
Shares
------
Balance, June 30, 1995................................. 16,000
Granted.............................................. --
Exercised............................................ --
Canceled............................................. 4,000
------
Balance, June 30, 1996................................. 12,000
------
Balance, June 30, 1996................................. 12,000
Granted.............................................. --
Exercised............................................ --
Canceled............................................. 12,000
------
Balance, June 30, 1997................................. --
------
Shares exercisable at June 30, 1997.................... --
======
LEASES
The Company leases its facilities under operating leases. Total rental
expense for the years ended June 30, 1997 and 1996 were $81,000 and $78,875,
respectively. The lease calls for payment by the Company of all operating costs
such as utilities, maintenance, taxes and liability insurance.
Future minimum rental commitments for the next five years as of June 30,
1997 on the aforementioned lease is as follows:
1998................................................... $ 79,375
1999................................................... 91,250
2000................................................... 101,875
2001................................................... 43,750
-----------
$316,250
===========
RELATED PARTY TRANSACTIONS
During 1997 and 1996, the Company sold materials and services to Biosearch
Medical Products Inc. (BMP), its former parent, for $31,257 and $20,787,
respectively. The Company also earned royalty income from BMP of $43,171 and
$48,415 for the years ended June 30, 1997 and 1996, respectively. Total amounts
owed to the Company by BMP were $19,794 and $7,390 at June 30, 1997 and 1996,
respectively.
In addition, BMP provides engineering and secretarial services to Hydromer.
These expenses amounted to $10,090 and $6,000 for the years ended June 30, 1997
and 1996, respectively. Amounts owed to BMP at June 30, 1997 and 1996,
respectively, were $597 and $500.
In 1997 and 1996, the Company purchased furniture and equipment from BMP
for $46,000 and $1,175, respectively.
Also, during 1997, the Company leased equipment and space from Biosearch
Medical Products, Inc., on a week-to-week basis. Total rental expense paid to
BMP was $6,000.
PRIOR PERIOD ADJUSTMENT
During the current year, it was discovered that certain royalty income was
unreported in prior years by a Licensee, resulting in an understatement of
reported assets as of June 30, 1995. The beginning accumulated deficit account
has been decreased by $162,000, due to the underaccrual of royalty receivable.
The restatement of accumulated deficit is recorded net of $0 tax as a result of
net operating loss carryforwards.
RESTATEMENT OF PRIOR YEAR'S FINANCIAL STATEMENTS
The prior year financial statements have been restated to reflect the
underreporting of royalty receivables from a Licensee. Due to this restatement,
accumulated deficit changed from $(2,531,317) to $(2,055,744) or $475,573 at
June 30, 1996. The net effect on the income per share was an increase of $.07
per share for the year ended June 30, 1996.
SUBSEQUENT EVENT
Subsequent to the year ended June 30, 1997, the Board of Directors
authorized a cash dividend of $.03 per share. The amount of the cash dividend
totals approximately $131,000.
- -------------------------------[Logo]HYDROMER---------------------------------11
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholders of
Hydromer, Inc.
We have audited the accompanying balance sheets of Hydromer, Inc. as of
June 30, 1997 and 1996 and the related statements of income, stockholders'
equity, and cash flows for the years then ended. These financial statements are
the responsibility of the company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Hydromer, Inc. as of June
30, 1997 and 1996, and the results of its operations and its cash flows for the
years then ended in conformity with generally accepted accounting principles.
/s/ Rosenberg Rich Baker Berman & Company
Bridgewater, New Jersey
July 22, 1997
12------------------------------[Logo]HYDROMER----------------------------------
<PAGE>
CORPORATE INFORMATION
BOARD OF DIRECTORS
MANFRED F. DYCK
Biosearch Medical Products Inc.
(Chairman, CEO, and President)
URSULA M. DYCK
Biosearch Medical Products Inc.
(Director)
MAXWELL BOROW, M.D.
Somerset Medical Center
(Chief of Surgery, retired)
DIETER HEINEMANN
Frankfurt Stock Exchange
(Specialist)
ROBERT H. BEA
Siemens Hearing Instruments Inc.
(Director of Quality Assurance and
Regulatory Affairs)
CORPORATE OFFICERS
MANFRED F. DYCK
Chairman Chief Executive Officer
President
MARK KLYPKA
Chief Financial Officer
Vice President
Finance and Administration
ROBERT D. FRAWLEY
Secretary, Corporate Counsel
REGISTRAR AND TRANSFER AGENT
First City Transfer Company
111 Wood Avenue South Suite 206
Iselin, New Jersey 08830
732-205-4517
AUDITORS
Rosenberg Rich Baker Berman
and Company
Bridgewater, New Jersey
LEGAL COUNSEL
Smith, Stratton, Wise, Heher
& Brennan
Princeton, New Jersey
CORPORATE OFFICE
35 Columbia Road
Branchburg, New Jersey 08876
908-526-2828
http://www.hydromer.com
Designed by Curran & Connors, Inc.
<PAGE>
[LOGO]HYDROMER
35 Columbia Road
Branchburg, New Jersey 08876
908-526-2828
http://www.hydromer.com
